Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Thoracic 1Breast 1

Conditions

Advanced Solid Tumours 5Ovarian Neoplasms 3Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Previously Treated Non Small Cell Lung Cancer 1Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation 1Muscle Invasive Bladder Cancer 1Lung Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Advanced Solid Tumors 1

Interventions

Paclitaxel 113Carboplatin 99Bevacizumab 59pembrolizumab 56liposomal doxorubicin 56Gemcitabine 42olaparib 39Topotecan 33niraparib 29Nivolumab 21Cisplatin 21Doxorubicin 17Cyclophosphamide 171-dodecylpyridoxal 16Drug Therapy 15Docetaxel 15avelumab 13Fulvestrant 11oregovomab 10Oxaliplatin 10rucaparib 9fludarabine 9Injections 9Fluorouracil 9veliparib 8mirvetuximab soravtansine 8atezolizumab 8Cetuximab 8fluzoparib 7cemiplimab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Ovarian Neoplasms × adavosertib × Clear all
NCT01357161 2023-09-21

A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)

Merck Sharp & Dohme LLC

Phase 2 Completed
136 enrolled 15 charts
Gynecologic

Ovarian Neoplasms

NCT02482311 2023-07-03

Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
92 enrolled
BreastGynecologicThoracic

Ovarian Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02610075 2023-07-03

Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.

AstraZeneca

Phase 1 Completed
62 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡